Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

Mihai Gheorghiade, Muthiah Vaduganathan, Andrew Ambrosy, Michael Böhm, Umberto Campia, John G F Cleland, Francesco Fedele, Gregg C. Fonarow, Aldo P. Maggioni, Alexandre Mebazaa, Mandeep Mehra, Marco Metra, Savina Nodari, Peter Pang, Piotr Ponikowski, Hani N. Sabbah, Michel Komajda, Javed Butler

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Although patients hospitalized with heart failure have relatively low in-hospital mortality, the post-discharge rehospitalization and mortality rates remain high despite advances in treatment. Most patients admitted for heart failure have normal or high blood pressure, but 15-25 % have low systolic blood pressure with or without signs and/or symptoms of hypoperfusion. All pharmacological agents known to improve the prognosis of patients with heart failure also reduce blood pressure, and this limits their use in patients with heart failure and low blood pressure (HF-LBP). However, patients with HF-LBP have much higher in-hospital and post-discharge mortality. In these patients, a conceptually important therapeutic target is to improve cardiac output in order to alleviate signs of hypoperfusion. Accordingly, the majority of these patients will require an inotrope as cardiac dysfunction is the cause of their low cardiac output. However, the short-term use of currently available inotropes has been associated with further decreases in blood pressure and increases in heart rate, myocardial oxygen consumption and arrhythmias. Agents that improve cardiac contractility without this undesirable effects should be developed. To the best of our knowledge, the epidemiology, pathophysiology and therapy of patients with HF-LBP have not been addressed thoroughly. In June 2010, a workshop that included scientists and clinicians was held in Rome, Italy. The objectives of this meeting were to (1) develop a working definition for HF-LBP, (2) describe its clinical characteristics and pathophysiology, (3) review current therapies and their limitations, (4) discuss novel agents in development and (5) create a framework for the design and conduct of future clinical trials.

Original languageEnglish (US)
Pages (from-to)107-122
Number of pages16
JournalHeart Failure Reviews
Volume18
Issue number2
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Hypotension
Heart Failure
Therapeutics
Blood Pressure
Low Cardiac Output
Mortality
Direction compound
Hospital Mortality
Oxygen Consumption
Cardiac Output
Italy
Signs and Symptoms
Cardiac Arrhythmias
Epidemiology
Heart Rate
Clinical Trials
Pharmacology
Hypertension
Education

Keywords

  • Blood pressure
  • Epidemiology
  • Heart failure
  • Hemodynamics
  • Outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gheorghiade, M., Vaduganathan, M., Ambrosy, A., Böhm, M., Campia, U., Cleland, J. G. F., ... Butler, J. (2013). Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Failure Reviews, 18(2), 107-122. https://doi.org/10.1007/s10741-012-9315-1

Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. / Gheorghiade, Mihai; Vaduganathan, Muthiah; Ambrosy, Andrew; Böhm, Michael; Campia, Umberto; Cleland, John G F; Fedele, Francesco; Fonarow, Gregg C.; Maggioni, Aldo P.; Mebazaa, Alexandre; Mehra, Mandeep; Metra, Marco; Nodari, Savina; Pang, Peter; Ponikowski, Piotr; Sabbah, Hani N.; Komajda, Michel; Butler, Javed.

In: Heart Failure Reviews, Vol. 18, No. 2, 03.2013, p. 107-122.

Research output: Contribution to journalArticle

Gheorghiade, M, Vaduganathan, M, Ambrosy, A, Böhm, M, Campia, U, Cleland, JGF, Fedele, F, Fonarow, GC, Maggioni, AP, Mebazaa, A, Mehra, M, Metra, M, Nodari, S, Pang, P, Ponikowski, P, Sabbah, HN, Komajda, M & Butler, J 2013, 'Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure', Heart Failure Reviews, vol. 18, no. 2, pp. 107-122. https://doi.org/10.1007/s10741-012-9315-1
Gheorghiade, Mihai ; Vaduganathan, Muthiah ; Ambrosy, Andrew ; Böhm, Michael ; Campia, Umberto ; Cleland, John G F ; Fedele, Francesco ; Fonarow, Gregg C. ; Maggioni, Aldo P. ; Mebazaa, Alexandre ; Mehra, Mandeep ; Metra, Marco ; Nodari, Savina ; Pang, Peter ; Ponikowski, Piotr ; Sabbah, Hani N. ; Komajda, Michel ; Butler, Javed. / Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. In: Heart Failure Reviews. 2013 ; Vol. 18, No. 2. pp. 107-122.
@article{c677a4d01213492c9fa12e44912c7a33,
title = "Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure",
abstract = "Although patients hospitalized with heart failure have relatively low in-hospital mortality, the post-discharge rehospitalization and mortality rates remain high despite advances in treatment. Most patients admitted for heart failure have normal or high blood pressure, but 15-25 {\%} have low systolic blood pressure with or without signs and/or symptoms of hypoperfusion. All pharmacological agents known to improve the prognosis of patients with heart failure also reduce blood pressure, and this limits their use in patients with heart failure and low blood pressure (HF-LBP). However, patients with HF-LBP have much higher in-hospital and post-discharge mortality. In these patients, a conceptually important therapeutic target is to improve cardiac output in order to alleviate signs of hypoperfusion. Accordingly, the majority of these patients will require an inotrope as cardiac dysfunction is the cause of their low cardiac output. However, the short-term use of currently available inotropes has been associated with further decreases in blood pressure and increases in heart rate, myocardial oxygen consumption and arrhythmias. Agents that improve cardiac contractility without this undesirable effects should be developed. To the best of our knowledge, the epidemiology, pathophysiology and therapy of patients with HF-LBP have not been addressed thoroughly. In June 2010, a workshop that included scientists and clinicians was held in Rome, Italy. The objectives of this meeting were to (1) develop a working definition for HF-LBP, (2) describe its clinical characteristics and pathophysiology, (3) review current therapies and their limitations, (4) discuss novel agents in development and (5) create a framework for the design and conduct of future clinical trials.",
keywords = "Blood pressure, Epidemiology, Heart failure, Hemodynamics, Outcomes",
author = "Mihai Gheorghiade and Muthiah Vaduganathan and Andrew Ambrosy and Michael B{\"o}hm and Umberto Campia and Cleland, {John G F} and Francesco Fedele and Fonarow, {Gregg C.} and Maggioni, {Aldo P.} and Alexandre Mebazaa and Mandeep Mehra and Marco Metra and Savina Nodari and Peter Pang and Piotr Ponikowski and Sabbah, {Hani N.} and Michel Komajda and Javed Butler",
year = "2013",
month = "3",
doi = "10.1007/s10741-012-9315-1",
language = "English (US)",
volume = "18",
pages = "107--122",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

AU - Gheorghiade, Mihai

AU - Vaduganathan, Muthiah

AU - Ambrosy, Andrew

AU - Böhm, Michael

AU - Campia, Umberto

AU - Cleland, John G F

AU - Fedele, Francesco

AU - Fonarow, Gregg C.

AU - Maggioni, Aldo P.

AU - Mebazaa, Alexandre

AU - Mehra, Mandeep

AU - Metra, Marco

AU - Nodari, Savina

AU - Pang, Peter

AU - Ponikowski, Piotr

AU - Sabbah, Hani N.

AU - Komajda, Michel

AU - Butler, Javed

PY - 2013/3

Y1 - 2013/3

N2 - Although patients hospitalized with heart failure have relatively low in-hospital mortality, the post-discharge rehospitalization and mortality rates remain high despite advances in treatment. Most patients admitted for heart failure have normal or high blood pressure, but 15-25 % have low systolic blood pressure with or without signs and/or symptoms of hypoperfusion. All pharmacological agents known to improve the prognosis of patients with heart failure also reduce blood pressure, and this limits their use in patients with heart failure and low blood pressure (HF-LBP). However, patients with HF-LBP have much higher in-hospital and post-discharge mortality. In these patients, a conceptually important therapeutic target is to improve cardiac output in order to alleviate signs of hypoperfusion. Accordingly, the majority of these patients will require an inotrope as cardiac dysfunction is the cause of their low cardiac output. However, the short-term use of currently available inotropes has been associated with further decreases in blood pressure and increases in heart rate, myocardial oxygen consumption and arrhythmias. Agents that improve cardiac contractility without this undesirable effects should be developed. To the best of our knowledge, the epidemiology, pathophysiology and therapy of patients with HF-LBP have not been addressed thoroughly. In June 2010, a workshop that included scientists and clinicians was held in Rome, Italy. The objectives of this meeting were to (1) develop a working definition for HF-LBP, (2) describe its clinical characteristics and pathophysiology, (3) review current therapies and their limitations, (4) discuss novel agents in development and (5) create a framework for the design and conduct of future clinical trials.

AB - Although patients hospitalized with heart failure have relatively low in-hospital mortality, the post-discharge rehospitalization and mortality rates remain high despite advances in treatment. Most patients admitted for heart failure have normal or high blood pressure, but 15-25 % have low systolic blood pressure with or without signs and/or symptoms of hypoperfusion. All pharmacological agents known to improve the prognosis of patients with heart failure also reduce blood pressure, and this limits their use in patients with heart failure and low blood pressure (HF-LBP). However, patients with HF-LBP have much higher in-hospital and post-discharge mortality. In these patients, a conceptually important therapeutic target is to improve cardiac output in order to alleviate signs of hypoperfusion. Accordingly, the majority of these patients will require an inotrope as cardiac dysfunction is the cause of their low cardiac output. However, the short-term use of currently available inotropes has been associated with further decreases in blood pressure and increases in heart rate, myocardial oxygen consumption and arrhythmias. Agents that improve cardiac contractility without this undesirable effects should be developed. To the best of our knowledge, the epidemiology, pathophysiology and therapy of patients with HF-LBP have not been addressed thoroughly. In June 2010, a workshop that included scientists and clinicians was held in Rome, Italy. The objectives of this meeting were to (1) develop a working definition for HF-LBP, (2) describe its clinical characteristics and pathophysiology, (3) review current therapies and their limitations, (4) discuss novel agents in development and (5) create a framework for the design and conduct of future clinical trials.

KW - Blood pressure

KW - Epidemiology

KW - Heart failure

KW - Hemodynamics

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84879464098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879464098&partnerID=8YFLogxK

U2 - 10.1007/s10741-012-9315-1

DO - 10.1007/s10741-012-9315-1

M3 - Article

C2 - 22581217

AN - SCOPUS:84879464098

VL - 18

SP - 107

EP - 122

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 2

ER -